Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serum markers in germ cell neoplasms.

N L Bartlett1, F S Freiha, F M Torti

  • 1Department of Medicine, Stanford University Medical Center, California.

Hematology/Oncology Clinics of North America
|December 1, 1991
PubMed
Summary

Serum tumor markers like AFP and BHCG are crucial for staging and monitoring testicular cancer patients. However, challenges remain with undetectable marker levels in some cases, necessitating further research for improved diagnostic tools.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Leukemia·2018
Same author

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Iron addiction: a novel therapeutic target in ovarian cancer.

Oncogene·2017
Same author

Effects of Anti-repulsive Guidance Molecule C (RGMc/Hemojuvelin) Antibody on Hepcidin and Iron in Mouse Liver and Tumor Xenografts.

Clinical & experimental pharmacology·2017

Area of Science:

  • Oncology
  • Biochemistry

Background:

  • Advances in testicular cancer treatment necessitate sensitive staging and monitoring methods.
  • Serum tumor markers, alongside imaging, have improved evaluation and treatment of seminomas and non-seminomatous germ cell tumors (NSGCT).

Purpose of the Study:

  • To highlight the importance of serum tumor markers in managing testicular cancer.
  • To discuss the limitations of current markers and the need for new diagnostic approaches.

Main Methods:

  • Review of the role of serum tumor markers (AFP, BHCG, LDH, PLAP, BFP) in testicular cancer.
  • Discussion of marker utility in diagnosis, post-treatment surveillance, and recurrence detection.
  • Analysis of challenges, including undetectable marker levels and persistent masses.

Main Results:

  • Elevated AFP and BHCG provide prognostic information and indicate disease persistence or recurrence.
  • Delayed marker clearance during chemotherapy suggests persistent disease.
  • Serum markers aid in defining therapy duration, minimizing treatment toxicity.

Conclusions:

  • Serum tumor markers are vital for testicular cancer management but have limitations, particularly in seminoma and some NSGCT cases.
  • The search for more sensitive and specific markers is ongoing.
  • Future advancements may include new markers and imaging techniques to differentiate residual masses.

Related Experiment Videos